Mark Talamonti to Neoadjuvant Therapy
This is a "connection" page, showing publications Mark Talamonti has written about Neoadjuvant Therapy.
Connection Strength
0.693
-
Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. Am J Surg. 2017 Mar; 213(3):521-525.
Score: 0.110
-
Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. Ann Surg Oncol. 2016 06; 23(6):1956-62.
Score: 0.104
-
Management Controversies and Treatment Strategies for Borderline Resectable Pancreatic Cancer. Cancer Treat Res. 2016; 168:59-75.
Score: 0.104
-
The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. J Surg Oncol. 2010 Oct 01; 102(5):539-42.
Score: 0.072
-
Neoadjuvant therapy for pancreatic cancer: a current review. J Surg Oncol. 2010 Mar 15; 101(4):315-20.
Score: 0.069
-
Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am J Surg. 2007 Mar; 193(3):389-93; discussion 393-4.
Score: 0.056
-
Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol. 2006 Aug; 13(8):1019-20.
Score: 0.054
-
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006 Feb; 13(2):150-8.
Score: 0.052
-
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
Score: 0.027
-
Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery. 2016 09; 160(3):714-24.
Score: 0.027
-
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010 Jun 01; 101(7):587-92.
Score: 0.018